Analysts’ Recent Ratings Updates for Cabaletta Bio (CABA)

Several brokerages have updated their recommendations and price targets on shares of Cabaletta Bio (NASDAQ: CABA) in the last few weeks:

• 10/10/2025 – Cabaletta Bio is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $14.00 price target on the stock.
• 10/10/2025 – Cabaletta Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 10/8/2025 – Cabaletta Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Cabaletta Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/5/2025 – Cabaletta Bio had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $15.00 price target on the stock.

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.